| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
1,5-Anhydro-D-mannitol targets gluconeogenesis, the metabolic pathway that synthesizes glucose from non-carbohydrate precursors. It has been shown to inhibit gluconeogenesis from lactate plus pyruvate and from substrates that enter the gluconeogenic pathway as triose phosphate. It is the specific substrate for EC 1.1.1.292, an enzyme involved in carbohydrate metabolism.
|
|---|---|
| ln Vitro |
In vitro, 1,5-Anhydro-D-mannitol has been shown to have significant effects on various types of cells. It has been reported to exhibit anti-inflammatory and anti-cancer effects. As the specific substrate for EC 1.1.1.292, it enables kinetic studies of bacterial anhydrofructose metabolism. It also serves as a control compound in experiments.
|
| ln Vivo |
In vivo activity data for 1,5-Anhydro-D-mannitol are limited. The compound has been shown to inhibit gluconeogenesis from lactate plus pyruvate and from substrates that enter the gluconeogenic pathway as triose phosphate. Its anti-inflammatory and anti-cancer effects have been reported, but specific animal model studies have not been detailed.
|
| Enzyme Assay |
Enzyme activity assays for 1,5-Anhydro-D-mannitol involve measuring its interaction with EC 1.1.1.292, the enzyme for which it is a specific substrate. Kinetic parameters such as Km and Vmax can be determined using standard enzyme kinetics methods. Binding studies can be performed to assess interactions with other enzymes and proteins.
|
| Cell Assay |
Cell-based assays for 1,5-Anhydro-D-mannitol may include evaluating its effects on gluconeogenesis in hepatocytes or other cell types. Anti-inflammatory effects can be assessed in macrophage cell lines by measuring cytokine production. Anti-cancer effects can be evaluated in cancer cell lines using viability assays.
|
| Animal Protocol |
In vivo animal protocols for 1,5-Anhydro-D-mannitol have not been extensively established. For gluconeogenesis inhibitors, standard models involve administering the compound to rodents and measuring blood glucose levels or hepatic glucose production. Specific protocols for this compound are not documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 1,5-Anhydro-D-mannitol are not extensively reported. The compound has a molecular weight of 164.16 and a molecular formula of C6H12O5. It is soluble in aqueous solutions. As a carbohydrate analog, it may be absorbed and metabolized through carbohydrate metabolic pathways.
|
| Toxicity/Toxicokinetics |
Toxicological data for 1,5-Anhydro-D-mannitol are limited. As a naturally occurring compound, it is generally considered to have low toxicity. However, formal safety assessments are lacking. Standard laboratory precautions should be observed when handling the compound.
|
| References | |
| Additional Infomation |
1,5-Ahydro-D-mannitol is a dehydrated sugar. It is functionally related to D-mannitol.
1,5-Anhydro-D-mannitol is a research-use-only compound. It is a gluconeogenesis inhibitor and the specific substrate for EC 1.1.1.292. It is the inactive analogue of 1,5-Anhydrosorbitol and can be used as an experimental control. It has been reported to exhibit anti-inflammatory and anti-cancer effects. It is used in studies of carbohydrate metabolism. |
| Molecular Weight |
164.16
|
|---|---|
| Exact Mass |
164.068
|
| CAS # |
492-93-3
|
| Related CAS # |
1,5-Anhydrosorbitol; 154-58-5
|
| PubChem CID |
445184
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.533g/cm3
|
| Boiling Point |
376.8ºC at 760 mmHg
|
| Flash Point |
181.7ºC
|
| Vapour Pressure |
3.21E-07mmHg at 25°C
|
| Index of Refraction |
1.58
|
| LogP |
-2.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
128
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)CO1
|
| InChi Key |
MPCAJMNYNOGXPB-KVTDHHQDSA-N
|
| InChi Code |
InChI=1S/C6H12O5/c7-1-4-6(10)5(9)3(8)2-11-4/h3-10H,1-2H2/t3-,4-,5-,6-/m1/s1
|
| Chemical Name |
(2R,3S,4R,5R)-2-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
1,5-Anhydro-D-mannitol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0916 mL | 30.4581 mL | 60.9162 mL | |
| 5 mM | 1.2183 mL | 6.0916 mL | 12.1832 mL | |
| 10 mM | 0.6092 mL | 3.0458 mL | 6.0916 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
